These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia. Khalaf A; de Beauchamp L; Kalkman E; Rattigan K; Himonas E; Jones J; James D; Shokry ESA; Scott MT; Dunn K; Tardito S; Copland M; Sumpton D; Shanks E; Helgason GV Sci Transl Med; 2024 Jun; 16(751):eadi5336. PubMed ID: 38865484 [TBL] [Abstract][Full Text] [Related]
3. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro. Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634 [TBL] [Abstract][Full Text] [Related]
4. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach. Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192 [TBL] [Abstract][Full Text] [Related]
5. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation. Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245 [TBL] [Abstract][Full Text] [Related]
6. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012 [TBL] [Abstract][Full Text] [Related]
7. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6. Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742 [TBL] [Abstract][Full Text] [Related]
8. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934 [TBL] [Abstract][Full Text] [Related]
9. CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine. Gu Y; Chen T; Meng Z; Gan Y; Xu X; Lou G; Li H; Gan X; Zhou H; Tang J; Xu G; Huang L; Zhang X; Fang Y; Wang K; Zheng S; Huang W; Xu R Blood; 2012 Dec; 120(24):4829-39. PubMed ID: 23074277 [TBL] [Abstract][Full Text] [Related]
11. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Trinh A; Khamari R; Fovez Q; Mahon FX; Turcq B; Bouscary D; Maboudou P; Joncquel M; Coiteux V; Germain N; Laine W; Dekiouk S; Jean-Pierre S; Maguer-Satta V; Ghesquiere B; Idziorek T; Quesnel B; Kluza J; Marchetti P Mol Metab; 2022 Jan; 55():101410. PubMed ID: 34863941 [TBL] [Abstract][Full Text] [Related]
12. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039 [TBL] [Abstract][Full Text] [Related]
13. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells. Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755 [TBL] [Abstract][Full Text] [Related]
14. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia. Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722 [TBL] [Abstract][Full Text] [Related]